Prescient Therapeutics Ltd
ASX:PTX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Kreate Group Oyj
OMXH:KREATE
|
FI |
|
Byke Hospitality Ltd
NSE:BYKE
|
IN |
|
S
|
SOM Distilleries and Breweries Ltd
BSE:507514
|
IN |
|
F
|
Fiskars Oyj Abp
OMXH:FSKRS
|
FI |
Prescient Therapeutics Ltd
Total Liabilities
Prescient Therapeutics Ltd
Total Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Prescient Therapeutics Ltd
ASX:PTX
|
Total Liabilities
AU$1.5m
|
CAGR 3-Years
12%
|
CAGR 5-Years
42%
|
CAGR 10-Years
9%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Total Liabilities
$207.6m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-4%
|
|
|
CSL Ltd
ASX:CSL
|
Total Liabilities
$19.2B
|
CAGR 3-Years
-1%
|
CAGR 5-Years
15%
|
CAGR 10-Years
15%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Total Liabilities
AU$1.2m
|
CAGR 3-Years
13%
|
CAGR 5-Years
60%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Total Liabilities
AU$748.6m
|
CAGR 3-Years
62%
|
CAGR 5-Years
57%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Total Liabilities
AU$11.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
27%
|
CAGR 10-Years
30%
|
|
Prescient Therapeutics Ltd
Glance View
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The firm is focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for a range of different cancers. Its Phase 1b clinical candidate PTX-100 is a drug that blocks the cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). PTX-200, a Phase 1b/2a clinical candidate is a PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Its OmniCAR, is an immune receptor platform enabling controllable T-cell activity and multi- antigen targeting with a single cell product is for the treatment of Acute Myeloid Leukemia (AML), Her2+ solid tumors, including breast, ovarian and gastric cancers and glioblastoma multiforme (GBM).
See Also
What is Prescient Therapeutics Ltd's Total Liabilities?
Total Liabilities
1.5m
AUD
Based on the financial report for Dec 31, 2025, Prescient Therapeutics Ltd's Total Liabilities amounts to 1.5m AUD.
What is Prescient Therapeutics Ltd's Total Liabilities growth rate?
Total Liabilities CAGR 10Y
9%
Over the last year, the Total Liabilities growth was 61%. The average annual Total Liabilities growth rates for Prescient Therapeutics Ltd have been 12% over the past three years , 42% over the past five years , and 9% over the past ten years .
